Vaccine Effectiveness, Burden and Impact Studies (VEBIS) - Healthcare worker cohort

Study identification

• PURI:
  https://redirect.ema.europa.eu/resource/1000000094
• EU PAS number:
  EUPAS1000000094
• Study ID:
  1000000094
• Official title and acronym:
  Vaccine Effectiveness, Burden and Impact Studies (VEBIS) - Healthcare worker cohort
• DARWIN EU® study:
  No
• Study countries:
  Croatia

  Estonia

  Greece

  Ireland

  Italy

  Latvia

  Poland

  Portugal

  Romania

  Spain
• Study description:
  Starting December 2021, ECDC-funded Vaccine Effectiveness, Burden and Impact (VEBIS) Framework Contract ECDC/2021/017 included the Lot 2: “Assessment of COVID-19 vaccine effectiveness among healthcare workers”. The VEBIS HCW VE cohort study included until 21 May 2023, 19 sites in 10 countries. Real-world VE studies can also answer questions about effectiveness by age group and risk factors, duration of vaccine protection, effectiveness of different vaccines, and effectiveness of the vaccine against new variants of SARS-CoV-2. The frequent testing independent of symptoms is especially relevant during the Omicron period, which is more associated with less severe or asymptomatic disease.
• Study status:
  Ongoing

Research institutions and networks

Institutions

European Centre for Disease Prevention and Control

EpiConcept

Study timelines

Date when funding contract was signed

Actual: 13/10/2021

Study start date

Actual: 13/10/2021

Date of final study report

Planned: 31/10/2025

Sources of funding

Other

More details on funding

Funding from European Centre for Disease Prevention and Control

Study protocol

Generic protocol for ECDC studies of COVID-19 vaccine effectiveness against confirmed SARS-CoV-2 using healthcare worker cohorts, version 3.0

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable